The Role of Interleukin-2 in the Treatment of Cancer
Recombinant human interleukin-2 became available for clinical use in the mid 1980s. Recent years have seen an enormous amount of clinical research with this cytokine and interleukin-2 has now been registered for use in a number of European countries for the treatment of metastatic renal cell carcinoma. This book is designed to provide the clinical oncologist wishing to use interleukin-2 with a basic background concerning the biology of the agent, a discussion concerning practical aspects, of its clinical use including management of toxicity and an overview of the clinical results together with a description of how this interesting cytokine might be developed in the future.
- Hardback | 200 pages
- 165.1 x 230 x 19.05mm | 539.96g
- 30 Sep 1993
- Kluwer Academic Publishers
- Dordrecht, Netherlands, United States
Table of contents
1. Introduction; J. Wagstaff. 2. Interleukin-2 as a single Agent - Dose, Scheduling and Optimum Immunomodularity Dose; L.M. Jost, R.A. Stahel. 3. Interleukin-2 and Lymphokine Activated Killer (LAK) Cells; S. Negrier, T.P. Philip. 4. Interleukin-2 Toxicity - Mechanisms and Management; J.W. Baars. 5. Interleukin-2 -Biology and Immunology: G. Parmiani, C. Gambacorti-Passerini. 6. Interleukin-2 and Tumour Eradication by Cytotoxic T Lymphocytes; C.J.M. Melief, W.M. Kast 7 Combination Treatment with Interleukin-2 and Chemotherapeutic Agents; A. von Rohr, N. Thatcher 8. Interleukin-2, Lymphocytes and Monoclonal Antibodies; R.L.H. Bolhuis, G. Stoter. 9. Interleukin-2 and Other Cytokines; J. Atzpodien. 10. Future Prospects for Interleukin-2 Therapy; C.R. Franks, P.R. Palmer.